Cat. No. 2252
Alternative Names: Adriamycin, NSC 123127
Chemical Name: 10-[(3-Amino-2,3,6-trideoxy-α-L-lyxohexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-5,12-naphthacenedione hydrochloride
Biological ActivityAntitumor antibiotic agent that inhibits DNA topoisomerase II. DNA intercalator that inhibits nucleic acid synthesis and induces apoptosis. Reduces intracellular tau levels.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Skladanowski and Konopa (1993) Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumour cells. Biochem.Pharmacol. 46 357. PMID: 8347161.
Patel et al (1997) Identification of yeast DNA topoisomerase II mutants resistant to the antitumor drug doxorubicin: implications for the mechanisms of doxorubicin action and cyotoxicity. Mol.Pharmacol. 52 658. PMID: 9380029.
Gewirtz (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem.Pharmacol. 57 727. PMID: 10075079.
Dickey et al (2006) Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression. Mol.Neurodegen. 1 6. PMID: 16930453.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: Doxorubicin hydrochloride, supplier, Antitumor, antibiotics, agent, inhibitors, DNA, topoisomerase, II, Isomerases, NSC123127
Find multiple products by catalog number
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.